CD274 and neoplasm: In a pancreatic ductal adenocarcinoma treatment study, oncolytic VACV and anti-PD-L1 combination also displayed good tumor attacking ability [146], and the complementary benefit of oncolytic VACV in ICB treatment was further confirmed.